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Cord blood transplantation (CBT) from an unrelated donor has been increasingly used as an alternative transplant method for adult patients without human leukocyte antigen (HLA)-compatible related or unrelated donors. [1] [2] [3] [4] However, the limited cell dose remains the main disadvantage of CBT, especially in adults, and might contribute to a higher incidence of graft failure and delayed hematopoietic recovery, leading to higher transplant-related mortality (TRM) or overall mortality after CBT.
The purpose of a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT) for hematologic malignancies is disease eradication and immunosuppression to overcome graft rejection. Although the standard myeloablative conditioning regimen prior to allo-HSCT has been total body irradiation (TBI) or busulfan combined with cyclophosphamide (CY) for patients with adult acute myeloid leukemia (AML), the role of an intensified conditioning regimen has been analyzed extensively in order to reduce the rate of posttransplant relapse and improve survival. [5] [6] [7] However, the majority of these studies analyzed patients receiving allo-HSCT using bone marrow (BM) or mobilized peripheral blood (PB) as a stem cell source. Therefore, an optimal myeloablative conditioning regimen prior to CBT for adult AML is still yet to be determined.
Granulocyte colony-stimulating factor (G-CSF) stimulates proliferation, differentiation, and functional activation of neutrophils. In clinical use, G-CSF is most commonly used for reducing the duration of neutropenia after chemotherapy and HSCT, and for the mobilization of hematopoietic stem/progenitor cells from the BM into PB for HSCT. Furthermore, since administration of G-CSF increases the susceptibility to cytarabine arabinoside (Ara-C) through induction of cell cycle entry of dormant leukemia cells, 8, 9 the efficacy of concomitant use of G-CSF and chemotherapy has been analyzed. 10 ,11 Several studies, as well as our single-institute studies, have demonstrated that G-CSF combined with myeloablative conditioning prior to allo-HSCT could be safely and effectively used for patients with myeloid malignancies in a single-arm trial. 9,12,13 However, there has 4 been no comparative study of transplant outcomes for AML after allo-HSCT following a conditioning regimen with or without G-CSF. This retrospective study is the first to assess the effect of a G-CSF combination in a myeloablative conditioning regimen for CBT on the transplant outcome in adult AML patients in Japan. Patients and methods are described in Supplemental methods.
Characteristics of patients and cord blood units are shown in Table 1 . The cumulative incidence of neutrophil recovery significantly differed among the four groups in univariate analysis (P<0.001) ( Figure 1A ). In the multivariate analysis, the hazard risk of neutrophil engraftment was significantly higher in the TBI≥10Gy+Ara-C/G-CSF+CY group (P<0.001) and lower in the TBI≥10Gy+other group (P=0.03) and TBI<10Gy+other or non-TBI group (P<0.001) compared with the TBI≥10Gy+Ara-C+CY group (Table 2) . Among patients achieving neutrophil engraftment, neutrophil recovery times were significantly shorter in the TBI≥10Gy+Ara-C/G-CSF+CY group compared with the TBI≥10Gy+Ara-C+CY group (P<0.001). The cumulative incidence of platelet recovery significantly differed among the four groups in univariate analysis (P<0.001) ( Figure 1B ).
Multivariate analysis showed no significant difference between the TBI≥10Gy+Ara-C+CY group and TBI≥10Gy+Ara-C/G-CSF+CY group (P=0.14). However, the hazard risk of platelet engraftment was significantly lower in the TBI≥10Gy+other group (P<0.001) and
TBI<10Gy+other or non-TBI group (P<0.001) compared with the TBI≥10Gy+Ara-C+CY group (Table 2) . Among patients achieving platelet engraftment, platelet recovery times were not significantly different among the four groups (P=0.32).
Among patients in the entire cohort, the cumulative incidence of TRM at 100 days and at 1 year was 17 % (95 % CI, 13 % to 20 %) and 22 % (95 % CI, 18 % to 26 %),
respectively. The cumulative incidence of TRM at 1 year did not differ significantly among the four groups in univariate analysis (P=0.19) ( Figure 1C ). Multivariate analysis of TRM, adjusting for other variables, showed no significant difference between the 5 TBI≥10Gy+Ara-C+CY group and the TBI≥10Gy+Ara-C/G-CSF+CY group (P=0.67),
TBI≥10Gy+other group (P=0.25), or TBI<10Gy+other or non-TBI group (P=0.95) ( Table 2 ).
The cumulative incidence of relapse at 3 years was 30 % (95 % CI, 25 % to 35 %) in the entire cohort. The cumulative incidence of relapse at 3 years did not differ significantly among the four groups (P=0.05) ( Figure 1D ). In multivariate analysis, the hazard risk of relapse was lower in the TBI≥10Gy+Ara-C/G-CSF+CY group (P=0.03), but not in the TBI≥10Gy+other group (P=0.94) and TBI<10Gy+other or non-TBI group (P=0.73) compared with the TBI≥10Gy+Ara-C+CY group (Table 2 ).
Among patients in the entire cohort, the probability of disease-free survival (DFS) and overall survival (OS) at 3 years in the entire cohort was 44 % (95 % CI, 39 % to 49 %) and 52 % (95 % CI, 46 % to 57 %), respectively. The probability of DFS at 3 years significantly differed among the four groups in univariate analysis (P=0.001) ( Figure 1E ).
The probability of DFS at 3 years was significantly better in TBI≥10Gy+Ara-C/G-CSF+CY group compared with TBI≥10Gy+Ara-C+CY group (P=0.02), the TBI≥10Gy+other group (P=0.002) and TBI<10Gy+other or non-TBI group (P=0.006). Multivariate analysis showed significantly decreased treatment failure in the TBI≥10Gy+Ara-C/G-CSF+CY group compared with the TBI≥10Gy+Ara-C+CY group (P=0.01) ( Table 2 ). The probability of OS at 3 years significantly differed among the four groups in univariate analysis (P=0.001) ( Figure 1F ). Multivariate analysis showed significantly decreased overall mortality in the TBI≥10Gy+Ara-C/G-CSF+CY group compared with the TBI≥10Gy+Ara-C+CY group (P=0.01) ( Table 2) . We also analyzed a subgroup of patients with standard risk (n=214) or high risk (n=221) at CBT. In standard-risk patients, the hazard risk of overall mortality (P=0.04), treatment failure (P=0.01) and relapse (P=0.002) was significantly lower in the TBI≥10Gy+Ara-C/G-CSF+CY group compared with the TBI≥10Gy+Ara-C+CY group, but not high-risk patients (Supplementary Table 1 , Supplementary Figure 1 , 2).
Anti-leukemia effects of allo-HSCT consist of leukemia eradication by both a 6 conditioning regimen of chemotherapy with or without radiation and the graft-versus-leukemia (GVL) effect. Since relapse is the most common cause of death after allo-HSCT, an intensified conditioning regimen or enhancement of GVL effects is needed to reduce the incidence of relapse. An intensified conditioning regimen has been analyzed extensively, because of the difficulty in controling the degree of GVL effects. Several improvements to a typical conditioning regimen have included the addition of other agents to a standard myeloablative regimen, a dose escalation of drugs or TBI, or administration of drugs other than CY. Among these, the addition of other agents to a standard myeloablative regimen has been the most commonly used. 5, 6 In fact, several studies have reported a decreased relapse incidence rate following intensified conditioning, but with a higher TRM, and did not achieve improved survival. 5, 7 Furthermore, the effect of adding high-dose Ara-C to a TBI/CY myeloablative conditioning regimen is controversial. 7 However, all of these studies analyzed patients receiving BM or mobilized PB stem cell transplantation from related or unrelated donors. This finding was not confirmed in CBT. In our study, neutrophil and platelet engraftment was significantly higher in the TBI≥10Gy+Ara-C+CY group compared with the TBI≥10Gy+other group, suggesting that the addition of Ara-C to TBI/CY was beneficial in terms of stable engraftment, but not for survival in CBT for AML.
G-CSF was originally identified as an agent for stimulation of neutrophil production. Although G-CSF is most commonly used to reduce the duration of neutropenia after chemotherapy, G-CSF is also commonly used for hematopoietic stem cell (HSC) mobilization for HSCT. Although the mechanism of HSC mobilization is not clearly understood, G-CSF could disrupt the contact between HSC in a BM niche, leading to the migration of HSC in a BM niche. In a mouse bone marrow transplantation (BMT) model, G-CSF prior to low-dose irradiation enhanced donor HSC engraftment. 14 This effect might be mainly due to the migration of recipient HSC from a BM niche by G-CSF treatment 7 before transplantation. In fact, our data showed that neutrophil engraftment was significantly higher in the TBI≥10Gy+Ara-C/G-CSF+CY group compared with the TBI≥10Gy+Ara-C+CY group. These data suggest that the effect of the addition of G-CSF to a conditioning regimen could enhance neutrophil engraftment after CBT.
It has been reported that the administration of G-CSF increased the susceptibility of the cell-cycle-specific agent Ara-C in leukemia cells in vitro and in a xenograft model. 8, 9, 15 In clinical studies, several regimens have attempted to demonstrate the efficacy of concomitant use of G-CSF with chemotherapy for newly diagnosed AML.
10,11
We hypothesized that the addition of G-CSF to a conditioning regimen might improve outcome in an allo-HSCT setting. In our study, relapse was significantly lower in the TBI≥10Gy+Ara-C/G-CSF+CY group compared with the TBI≥10Gy+Ara-C+CY group. In subgroup analysis, the effect of a G-CSF combination regimen for reduced relapse was significant in standard-risk, but not high-risk patients. This is similar to a previous prospective randomized study of concomitant use of G-CSF with chemotherapy by Löwenberg et al. 11 Further studies are required to confirm which subgroup of patients with AML could benefit from a G-CSF combination regimen in CBT to decrease relapse.
In conclusion, our data showed that the addition of G-CSF-combined Ara-C to a TBI+CY conditioning regimen showed a significantly higher incidence of neutrophil engraftment and significantly better DFS and OS and decreased relapse in CBT for AML.
Although these findings should be confirmed in prospective studies, a G-CSF-combined myeloablative conditioning regimen promotes better engraftment and survival results in CBT for AML. * Disease status at CBT was classified as standard risk or high risk; complete remission without poor prognostic karyotype according to the MRC10 criteria was classified as standard risk, whereas patients in all other situations were classified as high risk. † The number of HLA disparities was defined as low resolution for HLA-A, -B, and -DR in graft-versus-host direction.
Ara-C: cytosine arabinoside; CBT: cord blood transplantation; CY: cyclophosphamide; G-CSF: granulocyte colony-stimulating factor; GVHD:
graft-versus-host disease; HLA: human leukocyte antigen; TBI: total body irradiation. The only significant variables other than conditioning regimen were described in each endpoint. Variables considered in multivariate analysis were conditioning regimen (TBI≥10Gy+Ara-C+CY vs. TBI≥10Gy+Ara-C/G-CSF+CY vs. TBI≥10Gy+other vs.
TBI<10Gy+other or non-TBI), age (<40 vs. 
Definitions and end points
The study end points were neutrophil and platelet engraftment, transplant-related mortality (TRM), relapse, disease-free survival (DFS), and overall survival (OS). Neutrophil engraftment was defined as being achieved on the first of three consecutive days during which the absolute neutrophil count was at least 0.5 × 10 9 /L. Platelet engraftment was defined as being achieved on the first of three consecutive days when the platelet count was higher than 50 × 10 9 /L without transfusion support. TRM was defined as death during dose of cytarabine to the end of cytarabine dosing, and CY (total dose 120 mg/kg), which was originally described. [3] [4] [5] For disease status at CBT, patients in complete remission without poor prognostic karyotype were classified as standard risk, 6 whereas patients in all other situations were classified as high risk. The number of HLA disparities was defined as low resolution for HLA-A, -B, and -DR in the graft-versus-host direction. 415 of 438 (94.7 %) patients were administered G-CSF after CBT to shorten the duration of neutropenia.
Statistical analysis
Baseline patient and transplant characteristics were compared using the chi-square test or
Fischer's exact test for categorical variables and the Kruskal-Wallis test for continuous variables. The probability of DFS and OS was estimated according to the Kaplan-Meier method, and the groups were compared using the log-rank test. The probabilities of neutrophil and platelet engraftment, TRM, and relapse were estimated based on a cumulative incidence method to accommodate competing risks. Multivariate analysis was 0.16 Variables considered in multivariate analysis were conditioning regimen, age, patients' sex, GVHD prophylaxis, cord blood nucleated cell count, cord blood CD34+ cell count, HLA disparities, donor-recipient ABO compatibility, and year of CBT. Ara-C: cytosine arabinoside; CBT: cord blood transplantation; CI: confidence interval; CY: cyclophosphamide; G-CSF: granulocyte colony-stimulating factor; HR: hazard ratio; NA: not applicable; TBI: total body irradiation.
